Shionogi Company Limited

Bayer Schering Pharma Ag

Naoki Omori

Takeshi Endo

Takashi Yoshino

Kevin Bacon

Masami Takayama

Masaharu Kume

Kenji Matsuo

Yuusuke Tamura

Kyohei Hayashi

Aiko Omori

Klaus Urbahns

Florian Gantner

Satoko Matsukawa

Megumi Yamauchi

Tetsuo Kikuchi

Makoto Shimazaki

Toshiki Murata

Issei Kato

This invention provides new compounds having NPY Y5 antagonistic activity. The present inventors found that a compound of the formula (I): wherein Ris substituted or unsubstituted alkyl or the like; p, q and r are each independently 0 or 1; ring A is oxadiazole; and Ris substituted or unsubstituted alkyl or the like, has NPY Y5 antagonistic activity.

5-membered ring heteroaromatic derivatives having NPY Y5 receptor antagonistic activity

A compound which inhibits both of EGF receptor tyrosine kinase and HER2 tyrosine kinase is provided. A compound represented by the general formula (I): wherein Ris a group represented by the formula: wherein Ris a hydrogen atom, optionally substituted alkyl, etc.; Z is &#x2014;O&#x2014;, &#x2014;N(R)&#x2014;, etc.; Ris a hydrogen atom, alkyl, etc.; Ris a hydrogen atom, optionally substituted alkyl, etc.; Ris a hydrogen atom, optionally substituted alkyl, etc.; Ris optionally substituted alkyl, etc.; Wis an optionally substituted non-aromatic nitrogen-containing group; Ris a hydrogen atom, optionally substituted alkyl, etc.; Rand Rare independently a hydrogen atom, optionally substituted alkyl, etc.; X is &#x2014;O&#x2014;, &#x2014;S&#x2014;, or &#x2014;N(R)&#x2014;, etc.; Ris a hydrogen atom, alkyl, etc.; and A is phenyl optionally having a substituent, etc.,its pharmaceutically acceptable salt, or a solvate thereof.

Quinazoline derivatives having tyrosine kinase inhibitory activity

Growing community of inventors

Osaka, Japan

Naoki Omori